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Drouet and coll (5) described a pork-cat
syndrome or crossed allergy between
pork meat and cat epithelia in 1994. The
pattern shown by our patient diﬀered
slightly from previous reports. First, she
had no asthma attacks due to cats.
Secondly, she developed urticaria, rhini-
tis and asthma when exposed at work to
aerosols from evaporated pig-gut soak-
ing water containing albumin, c-globulin
and a 26 kDa protein. Albumin has
been reported to be allergens for food
allergies to pig gut and c-globulin for
allergy to beef, but none have ever been
reported to be aeroallergens. In conclu-
sion we demonstrated that our patient
had occupational asthma due to inhala-
tion of pig albumin, c-globulin and a 26-
kDa protein contained in evaporated
pig-gut soaking water.
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Acetylsalicylic acid (ASA) and other
nonsteroidal anti-inﬂammatory drugs
(NSAIDs) are among the drugs that most
commonly
cause adverse
reactions, and
in asthmatics
these reactions
can occur from
4.3 to 10.9%
(1, 2). In these
patients, cyclo-
oxygenase-2 (COX-2) inhibitors, when
indicated, have been proposed as a
therapeutic alternative although, even
with very recently marketed drugs, such
as rofecoxib, positive challenge was ob-
served in about one-third of the patients
with previous NSAID hypersensitivity
reactions (3); nevertheless, better results
were reported by other authors (4).
Severe selective allergic reactions to
COX-2 inhibitors have also been
described (5).
Etoricoxib is a recently introduced
member of the COX-2 very selective
inhibitors class of NSAIDs. It is available
in tablets of 60, 90 and 120 mg and
recommended for osteoarthritis and
chronic low back pain, rheumatoid arth-
ritis and for acute gouty arthritis and
primary dysmenorrhoea (6–7).
There are no previous reports in the
literature, to our knowledge, of adverse
reactions to etoricoxib.
The authors report a case of a 38-year-
old female, with a previous history of
adverse reaction to diﬀerent NSAIDs,
who required an elective arthroscopy to
her left knee and had no alternative drug
for post-surgery pain relieve. The patient
also has asthma and rhinitis and a family
history of anaphylaxis to a general
anaesthetic.
Our patient had a previous diagnostic
of ASA sensitivity evidenced by several
episodes of upper airway obstruction in
the sequence of ASA ingestion. These
episodes required treatment with intra-
venous corticosteroids for their resolu-
tion.
At the age of 23, attempts have been
made to introduce nimesulid and acet-
aminophen with poor results. The patient
developed dry cough, nausea and indis-
position, which were controlled with
H1-antihistamines.
Three years ago the patient had an
episode of upper airway obstruction, face
and hand oedema and generalized pruri-
tus following administration of intra-
muscular diclofenac.
Since then she has been avoiding all
NSAIDs.
About 7 months ago she developed
generalized urticaria and face angi-
oedema in the sequence of the ingestion
of 12.5 mg of rofecoxib, prescribed for
pain relief after her ﬁrst arthroscopy to
the left knee. This reaction was also
controlled with H1-antihistamines. At
present she needs a second arthroscopy
and has no available medication for
pain relief.
The patient was referred to our
department where we decided to perform
a single-blinded placebo-controlled chal-
lenge with 60 mg of etoricoxib. We star-
ted with the administration of placebo
followed by 20 and 40 mg of etoricoxib,
at 30-min intervals.
About 112 h after the beginning of the
challenge, the patient started to feel
nauseated, trembling and referred
abdominal pain and headache. The
symptoms remitted after treatment with
20 mg of ebastine by mouth.
Another single-blinded placebo chal-
lenge was tried with 50 mg of tramadol
1 week later and the patient developed
nausea and strong eructation and subse-
quently vomiting, symptoms that remitted
shortly after the administration of 20 mg
of ebastine. As the patient had an arthro-
scopy scheduled for the following day, we
A case of a placebo-
controlled positive
challenge to etoricoxib
with tolerance to
niflumic acid
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tried the administration of topic niﬂu-
mic acid on the volar surface of the
forearm, without any adverse reactions.
Then another placebo-controlled oral
trial was performed, with a cumulative
dose of 125 mg of niﬂumic acid, which
was negative, allowing the use of the
drug.
This case illustrates that not even the
most recent NSAIDs are free from
adverse reactions and that sometimes
other old alternatives must be consid-
ered.
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Vesicular and bullous eczema
in response to intravenous
immunoglobulins (IVIG)
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Standard (0.4 g/kg/day) and high dose
(2 g/kg/day) intravenous immunoglobu-
lins (IVIG) are
used for therapy
of several der-
matological and
neurological
autoimmune
diseases (e.g.
dermatomyosi-
tis, pemphigus
vulgaris, multifocal motor neuropathy)
(1–3). Cutaneous adverse eﬀects to IVIG
have only rarely been reported and
encompass case reports on eczema, alo-
pezia, erythema multiforme, and ana-
phylactic reactions; the latter, however, is
usually explanatory by a deﬁciency in
IgA and can be prevented by measuring
IgA levels prior to treatment.
We want to draw attention to a peculiar
cutaneous side eﬀect which may be more
frequent than reported as it resembles
common vesicular eczema (pompholyx,
dyshidrotic eczema), andwhichmight lead
to undue interruption of therapy for fear
of a more severe bullous drug reaction.
A 33-year-old patient with multifocal
motor neuropathy received 0.4 g/kg/day
IVIG for 5 days. One day after com-
pletion he developed a vesicular eczema
at the lateral aspect of his ﬁngers, which
within 3 days extended to volar aspect
of ﬁngers and to both palms while
vesicles progressed into bullae. He also
developed a slightly scaling erythema on
the face and capillitium. When after
10 days treatment with topical cortico-
steroids was initiated bullae started to
empty clear ﬂuid and the lesions showed
extensive desquamation and healed
within 1 week.
For a second course of IVIG the
patient received systemic antihistamines
and remained under close observation.
One day after completion he again
developed vesicular eczema, which how-
ever, ran a markedly milder course with
fewer lesions and without bullae. Local
corticosteroids were not necessary. IVIG
were then continued and during the
subsequent seven courses the patient
developed only very mild vesicular reac-
tions. When he stopped taking antihista-
mines after the fourth course, there was
slight aggravation of the vesicular reac-
tion, but it was transient and did not
recur after the following infusions even
though antihistamines were not resumed.
For allergologic work-up after the
severe bullous reaction we performed
(epicutaneous) patch testing as well as
prick testing with the corresponding
IVIG preparation and preservatives such
as chlorocresol and sulﬁte. All reactions
but controls remained negative (patch
test up to day 7).
There are only few reports on vesicular
eczema or pompholyx after treatment
with IVIG: 3 of 23 patients (4) and 1 of
10 patients with IVIG for neurological
diseases (5). Extension of vesicular ecze-
ma to arms, breast and head area was
described for only few of these cases.
The pathogenesis of this adverse eﬀect
is not well understood (4, 5). It may be a
unique side eﬀect of IVIG therapy, as it
has not been reported for other medica-
tions (4). It has been suggested to occur
only in those patients, which show very
high plasma IgG concentrations directly
after administration of IVIG (>3000 mg/
dl) (5), but this was not the case in our
patient who showed only slightly elevated
IgG (11.6–19.7 g/l). However, he presen-
ted with remarkably high IgE levels
(1806 U/ml) already before IVIG treat-
ment, which were not associated with
lymphoma, other myeloic disorders or
atopic diathesis. Since imbalances in
plasma levels of immunoglobulins are
known to be associated with conditions
resembling atopic eczema (6) we speculate
that IVIG therapy may result in devel-
opment of dyshidrotic eczema in patients
with a certain, transient imbalance in
serum immunoglobulins.
If IVIG therapy is to be continued in
these cases, companies recommend pro-
phylactic administration of corticoster-
oids and antihistamines. However,
according to our experience and to the
few published reports we suggest that
vesicular eczemas following IVIG
A peculiar cutaneous
side of IVIG, i.e. bullous
eczema, which might
lead to undue
interruption of therapy.
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